Study shows accrued benefit of lower LDL-C over time for Repatha
US biotech giant Amgen (Nasdaq: AMGN) today presented results from the FOURIER-OLE studies – the open-label extension studies of the Repatha FOURIER cardiovascular outcomes trial at the European Society of Cardiology (ESC) Annual Meeting being held in Barcelona, Spain.
FOURIER-OLE evaluated more than 6,600 patients who were followed for a median of five years, with some patients receiving Repatha (evolocumab) for up to 8.4 years. This is the longest trial of a PCSK9 inhibitor to-date, Amgen noted. Repatha is already a blockbuster drug, generating second-quarter 2022 sales were $325 million, +14% year-on-year.
The data showed tolerability of Repatha, as well as consistent and sustainable lowering of LDL-C. The data also suggest that earlier use and longer treatment duration deliver a lower incidence of cardiovascular (CV) events beyond what has been shown in the parent FOURIER trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze